A5022568571- Biosimilars and Bioanalytical Methods
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Protein Degradation and Inhibitors
- Monoclonal and Polyclonal Antibodies Research
- Click Chemistry and Applications
- Protein Tyrosine Phosphatases
- Signaling Pathways in Disease
- Galectins and Cancer Biology
- CRISPR and Genetic Engineering
- PARP inhibition in cancer therapy
Reproductive Science Center
2024
Massachusetts General Hospital
2022-2024
Harvard University
2022-2023
Uterine serous cancer (USC) comprises around 10% of all uterine cancers. However, USC accounts for approximately 40% deaths, which is attributed to tumor aggressiveness and limited effective treatment. Galectin 3 (Gal3) has been implicated in promoting aggressive features some malignancies. Gal3's role pathology lacking.
Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
<div>Abstract<p>Significant strides have been made in the development of precision therapeutics for cancer. Aberrantly expressed glycoproteins represent a potential avenue therapeutic development. The MUC16/CA125 glycoprotein serves as biomarker disease and driver malignant transformation epithelial ovarian Previously, we demonstrated proof-of-principle approach to selectively targeting MUC16<sup>+</sup> cells. In this report, performed synthetic lethal kinase screen...
Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
<div>Abstract<p>Significant strides have been made in the development of precision therapeutics for cancer. Aberrantly expressed glycoproteins represent a potential avenue therapeutic development. The MUC16/CA125 glycoprotein serves as biomarker disease and driver malignant transformation epithelial ovarian Previously, we demonstrated proof-of-principle approach to selectively targeting MUC16<sup>+</sup> cells. In this report, performed synthetic lethal kinase screen...
Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
Abstract Significant strides have been made in the development of precision therapeutics for cancer. Aberrantly expressed glycoproteins represent a potential avenue therapeutic development. The MUC16/CA125 glycoprotein serves as biomarker disease and driver malignant transformation epithelial ovarian Previously, we demonstrated proof-of-principle approach to selectively targeting MUC16+ cells. In this report, performed synthetic lethal kinase screen using human kinome RNAi library identified...